(STIM) Neuronetics - Ratings and Ratios
Therapy System, Magnetic Stimulation, Brain Treatment, Depression Treatment
STIM EPS (Earnings per Share)
STIM Revenue
Description: STIM Neuronetics
Neuronetics Inc (NASDAQ:STIM) is a healthcare company specializing in non-invasive treatments for neurohealth disorders, primarily major depressive disorder (MDD). The companys flagship product, NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) technology to stimulate areas of the brain associated with mood regulation.
From a business perspective, Neuronetics sells its NeuroStar system through a sales and customer support team, targeting psychiatrists as its primary customers. With a presence in the US and international markets, the company has established itself as a player in the mental health treatment landscape. Key performance indicators (KPIs) to watch include revenue growth, customer acquisition rates, and the expansion of its customer support infrastructure.
To gauge the companys financial health, we can examine metrics such as revenue per user, gross margin, and operating expenses as a percentage of revenue. Additionally, we can look at the companys cash burn rate and its ability to generate cash from operations. With a market capitalization of $232.67M, Neuronetics financials will be closely tied to its ability to drive adoption of its NeuroStar system and expand its customer base.
From a growth perspective, we can analyze the companys progress in expanding its market share, increasing its sales and marketing efforts, and developing new applications for its TMS technology. Key metrics to monitor include the number of NeuroStar systems sold, the growth rate of its customer base, and the companys ability to secure partnerships or collaborations that can drive further adoption.
As a trading analyst, we can also examine the stocks price action and trading metrics, such as trading volume, short interest, and institutional ownership. While the current price is $3.57, we can look at the stocks historical volatility, its relative strength index (RSI), and its moving average convergence divergence (MACD) to gauge potential trading opportunities.
STIM Stock Overview
| Market Cap in USD | 220m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2018-06-28 |
STIM Stock Ratings
| Growth Rating | 17.9% |
| Fundamental | 24.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 199% |
| Analyst Rating | 4.0 of 5 |
STIM Dividends
Currently no dividends paidSTIM Growth Ratios
| Growth Correlation 3m | -34.4% |
| Growth Correlation 12m | 63.9% |
| Growth Correlation 5y | -60.6% |
| CAGR 5y | 0.74% |
| CAGR/Max DD 3y | 0.01 |
| CAGR/Mean DD 3y | 0.01 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 0.28 |
| Beta | 0.698 |
| Volatility | 107.17% |
| Current Volume | 1705.1k |
| Average Volume 20d | 1473k |
| Stop Loss | 2.5 (-9.7%) |
| Signal | -0.99 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-48.3m TTM) > 0 and > 6% of Revenue (6% = 6.67m TTM) |
| FCFTA -0.24 (>2.0%) and ΔFCFTA 11.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.50% (prev 64.18%; Δ -38.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.26 (>3.0%) and CFO -34.5m > Net Income -48.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (66.2m) change vs 12m ago 120.2% (target <= -2.0% for YES) |
| Gross Margin 56.15% (prev 71.79%; Δ -15.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 96.00% (prev 74.44%; Δ 21.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.74 (EBITDA TTM -38.6m / Interest Expense TTM 7.20m) >= 6 (WARN >= 3) |
Altman Z'' -16.24
| (A) 0.21 = (Total Current Assets 56.1m - Total Current Liabilities 27.8m) / Total Assets 134.7m |
| (B) -3.29 = Retained Earnings (Balance) -442.6m / Total Assets 134.7m |
| warn (B) unusual magnitude: -3.29 — check mapping/units |
| (C) -0.36 = EBIT TTM -41.4m / Avg Total Assets 115.7m |
| (D) -4.28 = Book Value of Equity -441.9m / Total Liabilities 103.1m |
| Total Rating: -16.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.96
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -12.03% = -5.0 |
| 3. FCF Margin -29.22% = -7.50 |
| 4. Debt/Equity 2.24 = 0.40 |
| 5. Debt/Ebitda -1.58 = -2.50 |
| 6. ROIC - WACC (= -60.33)% = -12.50 |
| 7. RoE -193.8% = -2.50 |
| 8. Rev. Trend 75.78% = 5.68 |
| 9. EPS Trend 17.41% = 0.87 |
What is the price of STIM shares?
Over the past week, the price has changed by -24.93%, over one month by -21.75%, over three months by -24.11% and over the past year by +255.13%.
Is Neuronetics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STIM is around 2.77 USD . This means that STIM is currently overvalued and has a potential downside of 0%.
Is STIM a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the STIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 134.7% |
| Analysts Target Price | 6.5 | 134.7% |
| ValueRay Target Price | 3.1 | 10.1% |
Last update: 2025-09-03 04:48
STIM Fundamental Data Overview
CCE Cash And Equivalents = 11.1m USD (Cash And Short Term Investments, last quarter)
P/S = 1.9819
P/B = 8.1112
Beta = 1.783
Revenue TTM = 111.1m USD
EBIT TTM = -41.4m USD
EBITDA TTM = -38.6m USD
Long Term Debt = 55.5m USD (from longTermDebt, last quarter)
Short Term Debt = 5.32m USD (from shortTermDebt, last quarter)
Debt = 60.9m USD (Calculated: Short Term 5.32m + Long Term 55.5m)
Net Debt = 69.7m USD (from netDebt column, last quarter)
Enterprise Value = 269.9m USD (220.2m + Debt 60.9m - CCE 11.1m)
Interest Coverage Ratio = -5.74 (Ebit TTM -41.4m / Interest Expense TTM 7.20m)
FCF Yield = -12.03% (FCF TTM -32.5m / Enterprise Value 269.9m)
FCF Margin = -29.22% (FCF TTM -32.5m / Revenue TTM 111.1m)
Net Margin = -43.47% (Net Income TTM -48.3m / Revenue TTM 111.1m)
Gross Margin = 56.15% ((Revenue TTM 111.1m - Cost of Revenue TTM 48.7m) / Revenue TTM)
Tobins Q-Ratio = -0.61 (set to none) (Enterprise Value 269.9m / Book Value Of Equity -441.9m)
Interest Expense / Debt = 2.96% (Interest Expense 1.80m / Debt 60.9m)
Taxrate = 21.0% (US default)
NOPAT = -41.4m (EBIT -41.4m, no tax applied on loss)
Current Ratio = 2.02 (Total Current Assets 56.1m / Total Current Liabilities 27.8m)
Debt / Equity = 2.24 (Debt 60.9m / last Quarter total Stockholder Equity 27.1m)
Debt / EBITDA = -1.58 (Net Debt 69.7m / EBITDA -38.6m)
Debt / FCF = -1.87 (Debt 60.9m / FCF TTM -32.5m)
Total Stockholder Equity = 24.9m (last 4 quarters mean)
RoA = -35.87% (Net Income -48.3m, Total Assets 134.7m )
RoE = -193.8% (Net Income TTM -48.3m / Total Stockholder Equity 24.9m)
RoCE = -51.43% (Ebit -41.4m / (Equity 24.9m + L.T.Debt 55.5m))
RoIC = -53.10% (NOPAT -41.4m / Invested Capital 77.9m)
WACC = 7.24% (E(220.2m)/V(281.1m) * Re(8.59%)) + (D(60.9m)/V(281.1m) * Rd(2.96%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 8.50%
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -32.5m)
EPS Correlation: 17.41 | EPS CAGR: 20.89% | SUE: -0.59 | # QB: 0
Revenue Correlation: 75.78 | Revenue CAGR: 35.59% | SUE: N/A | # QB: None
Additional Sources for STIM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle